...severe and end stage chronic kidney diseases-EpiTer-2 data...
Background and Aims: We evaluated the effectiveness and safety of pan-genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/V... G Indolfi,P Easterbrook,RLE Giometto - 《Liver International》 被引量: 0发表: 2024年 加载更多来源...